$3.520
-0.020 (-0.56%)Al cierre
Comparativa sectorial de GALT
In the context of the broader market, GALT competes directly with industry leaders such as ZURA and OGCP. With a market capitalization of $357.01M, it holds a significant position in the sector. When comparing efficiency, GALT's gross margin of N/A stands against ZURA's N/A and OGCP's N/A. Such benchmarking helps identify whether Galectin Therapeutics Inc is trading at a premium or discount relative to its financial performance.
Desempeño financiero de Galectin Therapeutics Inc
Galectin Therapeutics has reported consistent losses, with a net income loss of $9.11 million in Q2 2026, a 21% increase from the previous year. The company's EPS for Q2 2026 is -0.14, reflecting ongoing financial struggles.
Financials
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.